Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
1.
Ethical Human Psychology & Psychiatry ; 25(1):66-88, 2023.
Article in English | Academic Search Complete | ID: covidwho-2301246

ABSTRACT

Two publications by Merzon and colleagues in the Journal of Attention Disorders (JAD) suggest that attention-deficit hyperactivity disorder (ADHD) increases the risk of COVID-19 infections (2020) and severe outcomes (2021). Adherence to stimulant treatments was recommended to attenuate the spread of the pandemic (2020). The conclusions of these timely studies attracted considerable attention, probably due to their wide-scope implications for the public health. But how valid are they? Furthering our earlier critique published in this journal, the current article outlines seven severe gaps in these publications, including inconsistencies in the definitions and rates of ADHD, inadequate definition for ADHD medications, omissions of crucial information, unsuitable analyses, and unmet declarations regarding conflicts of interests and data availability. In fact, the latter, which constitutes a repeated avoidance of data sharing (up to this day, March 28, 2023), seems to have led the editor-in-chief of JAD to propose the write-up of the current article (which he then judged, after the peer review process, as "worthy of publication," but also that JAD is "not the best placement" of its publication—despite its specific focus on several JAD articles). To complete the picture regarding this burning public health issue, this article also provides a glimpse into the problematic happenings that took place behind the scenes, which included a personal defamation and various stalling tactics, along with an elaborated and fully-referenced response that was sent by the authors of the current article to the reviewers and the editor-in-chief of JAD in real time (Appendix). Together, the discrepancies and problematic ethical conducts that are exposed in the current article suggest that the speculation regarding the link between a neurodevelopmental diagnosis (ADHD) and a respiratory virus (COVID-19) has not been subjected to adequate scientific inquiry. On the contrary, the lack of transparency, the observed gaps, and the existing extensive literature on stimulant-related cardiovascular risks, including the recently published guidelines for starting ADHD medications by one of the authors of the 2021 study, raise concerns regarding the potentially dangerous implications of stimulant use during a global epidemic. [ FROM AUTHOR] Copyright of Ethical Human Psychology & Psychiatry is the property of Springer Publishing Company, Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)

2.
Front Psychiatry ; 11: 594816, 2020.
Article in English | MEDLINE | ID: covidwho-2272007

ABSTRACT

Among the symptoms of COVID-19 fever, general malaise, pain and aches, myalgia, fatigue, and headache can affect the quality of life of patients, even after the end of the acute phase of the infection and can be long lasting. The current treatment of these symptoms, also because COVID-19 patients have been asked not to use non-steroidal anti-inflammatory drugs (NSAIDs), in particular ibuprofen are often unsatisfactory. Among the above mentioned symptoms malaise and fatigue seem the most difficult to treat. In this case report we describe the use of kratom (Mitragyna speciosa) by a patient with confirmed COVID-19 infection. What we observed was a fast and sustained relieve of the above mentioned symptoms.

3.
Brain Res Bull ; 187: 155-161, 2022 09.
Article in English | MEDLINE | ID: covidwho-2284649

ABSTRACT

Adults with attention deficit hyperactivity disorder (ADHD) have shown higher infection rates and worse outcomes from COVID-19. Stimulant medications are prescribed as the first-line treatment for ADHD in adults and mitigate risk of negative ADHD-related health outcomes, but little is known about the association between stimulant medications and COVID-19 outcomes. The objective of this study was to assess the risks of severe COVID-19 outcomes among people with ADHD who were prescribed stimulant medications versus those who were not. This retrospective cohort study used electronic health records in the TriNetX research database. We assessed records of adults with ADHD diagnosed with COVID-19 between January 1, 2020 and June 30, 2021. The stimulant cohort consisted of 28,011 people with at least one stimulant prescription; the unmedicated cohort comprised 42,258 people without prescribed stimulants within 12 months prior to their COVID infection. Multiple logistic regression modeling was utilized to assess the presence of critical care services or death within 30 days after the onset of COVID diagnoses, controlling for patient demographics, and comorbid medical and mental health conditions. The stimulant cohort was less likely to utilize emergency department, hospital, and intensive care services than the unmedicated cohort, and had significantly lower 30-day mortality. Further research, including prospective studies, is needed to confirm and refine these findings.


Subject(s)
Attention Deficit Disorder with Hyperactivity , COVID-19 , Central Nervous System Stimulants , Adult , Attention Deficit Disorder with Hyperactivity/drug therapy , Attention Deficit Disorder with Hyperactivity/epidemiology , Central Nervous System Stimulants/adverse effects , Humans , Prospective Studies , Retrospective Studies
4.
Int J Environ Res Public Health ; 19(22)2022 Nov 12.
Article in English | MEDLINE | ID: covidwho-2110097

ABSTRACT

In March 2020, the WHO announced the COVID-19 pandemic, which has been ongoing for over 2 years. To stop the spread of the virus, the governments of many countries decided to introduce reasonable social restrictions that were suitable for pandemic waves. This led to radical changes in people's lives, especially among students, who are very active in society. Before COVID-19, being of student age was associated with the highest frequency of stimulants use. It is important to note that drugs are taken disparately in various areas. Therefore, using the Computer-Assisted Web Interview type of study, the impact of the pandemic on the use of alcohol, cannabinoids, psychostimulants (e.g., amphetamine, methamphetamine, ecstasy) and sedatives (e.g., zolpidem, zopiclone, alprazolam, lorazepam, etc.) was assessed among students from European countries. The questionnaire included single- and multiple-answer questions. The first part concerned sociodemographic questions, while the second included questions about the use of stimulants in the last 3 months prior to participation in the study. Distribution of the survey covered the period from 31 January 2016 to 30 April 2021. A total of 17,594 European students participated in the study. The vast majority of participants were women (80.4%) and students of non-medical universities (77.2%) living in Eastern European countries (86.1%). Of all students, 15,613 (89.6%) reported alcohol drinking, 2538 (14.1%) the use of cannabinoids, 650 (3.6%) psychostimulants, and 2252 (12.5%) sedatives in the past three months. It has been shown that women are far less likely to use alcohol (OR 0.81), psychostimulants (OR 0.44) and cannabinoids (OR 0.49), while they are more likely to use sedatives (OR 1.41). During the COVID-19 pandemic, the consumption of alcohol (OR 0.55) and psychostimulants (OR 0.72) decreased and that of sleep medications increased (OR 1.17). To conclude, the COVID-19 pandemic influenced the pattern of stimulants used by students in European countries. The restriction of social interactions contributed to the decrease in the consumption of alcohol and psychostimulants but increased the use of sedatives and the frequency of their use. Women were found to use sedatives more often, while men preferred to drink alcohol and use cannabinoids or psychostimulants. It has also been shown that students of Central and Eastern Europe more often use alcohol and sedatives, while in Southern European countries psychostimulants and cannabinoids are preferred.


Subject(s)
COVID-19 , Cannabinoids , Humans , Female , Male , COVID-19/epidemiology , Pandemics , Hypnotics and Sedatives/therapeutic use , Cannabinoids/therapeutic use , Students
5.
Trials ; 23(1): 342, 2022 Apr 23.
Article in English | MEDLINE | ID: covidwho-2098441

ABSTRACT

BACKGROUND: Methamphetamine use could jeopardize the current efforts to address opioid use disorder and HIV infection. Evidence-based behavioral interventions (EBI) are effective in reducing methamphetamine use. However, evidence on optimal combinations of EBI is limited. This protocol presents a type-1 effectiveness-implementation hybrid design to evaluate the effectiveness, cost-effectiveness of adaptive methamphetamine use interventions, and their implementation barriers in Vietnam. METHOD: Design: Participants will be first randomized into two frontline interventions for 12 weeks. They will then be placed or randomized to three adaptive strategies for another 12 weeks. An economic evaluation and an ethnographic evaluation will be conducted alongside the interventions. PARTICIPANTS: We will recruit 600 participants in 20 methadone clinics. ELIGIBILITY CRITERIA: (1) age 16+; (2) Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) scores ≥ 10 for methamphetamine use or confirmed methamphetamine use with urine drug screening; (3) willing to provide three pieces of contact information; and (4) having a cell phone. OUTCOMES: Outcomes are measured at 13, 26, and 49 weeks and throughout the interventions. Primary outcomes include the (1) increase in HIV viral suppression, (2) reduction in HIV risk behaviors, and (3) reduction in methamphetamine use. COVID-19 response: We developed a response plan for interruptions caused by COVID-19 lockdowns to ensure data quality and intervention fidelity. DISCUSSION: This study will provide important evidence for scale-up of EBIs for methamphetamine use among methadone patients in limited-resource settings. As the EBIs will be delivered by methadone providers, they can be readily implemented if the trial demonstrates effectiveness and cost-effectiveness. TRIAL REGISTRATION: ClinicalTrials.gov NCT04706624. Registered on 13 January 2021. https://clinicaltrials.gov/ct2/show/NCT04706624.


Subject(s)
Amphetamine-Related Disorders , HIV Infections , Methamphetamine , Opioid-Related Disorders , Adolescent , Amphetamine-Related Disorders/diagnosis , COVID-19 , HIV Infections/prevention & control , Humans , Methadone/therapeutic use , Methamphetamine/adverse effects , Opioid-Related Disorders/diagnosis , Opioid-Related Disorders/drug therapy , Randomized Controlled Trials as Topic
6.
Archives of Disease in Childhood ; 107(Suppl 2):A322, 2022.
Article in English | ProQuest Central | ID: covidwho-2019889

ABSTRACT

AimsTraditional in-person ADHD medication review is part of the Neurodevelopmental Service led by a community paediatrician at a district general hospital in North Wales. Consequent to COVID-19 pandemic lockdown in March 2020, the service was delivered virtually to limit infection risk, via telephone and web-based video Attend Anywhere platform. Although aligned with the European ADHD Guidelines Group recommendations, there was no past report of user experience on such contingent service delivery. A survey was therefore designed to evaluate user satisfaction and preference on the new locally implemented virtual ADHD medication review clinics in CYP during the COVID-19 UK-wide lockdown.MethodsFamilies with ADHD CYP who had attended their first virtual ADHD medication consultation between 6 April to 12 May 2020 were surveyed via telephone in August 2021. Parent/carer and/or CYP with ADHD were requested for consent to provide independent satisfaction and preference ratings scores (5 very satisfied/strongly agreed, 4 satisfied/agreed, 3 neutral, 2 unsatisfied/disagreed and 1 very unsatisfied/strongly disagreed). Demography and clinical data were retrieved from respective clinic review letters. Microsoft Excel 2016 was used to analyse anonymised survey data.ResultsAmong nine clinics over the 6-week surveyed period, 47% (30/64) of the families of ADHD CYP of which 73% (22/30) male, were available and completed the survey. Responses were provided by all except one (29/30) mother and 37% (7/22 male and 4/8 female) of the surveyed ADHD cohort. The median (range) age in years for male was 13 (9 to 19) and female 14 (9 to 16). Their ADHD diagnosis ranged from 1 to 10 years with 63% identified with co-morbidities. Forty-percent experienced sleep issues with a-third benefiting for melatonin use. Among 93% of the cohort taking stimulants, 20% warrant medication only for schooling. Collective ratings were based on 10 telephone, 9 video and 11 both modes of virtual consultations. Greater satisfaction was reported from mothers than children on the quality of virtual consultations with highest ratings in screen (95% vs 86%) compared to access (70% vs 64%) and audio (79% vs 64%). Preferences on consultation modes for both mothers and children were similar with highest ratings for face-to-face (79% vs 82%), followed by video (61% vs 70%) and lowest via telephone (57% vs 55%) call.ConclusionThis parental and ADHD CYP survey results on the local virtually delivered ADHD medication reviews during the COVID-19 nationwide crisis, revealed despite high satisfaction on the quality of virtual consultations, greater for video screen than telephone audio only call, both users expressed greater preference for in-person consultations. Following COVID-19 de-escalation, while resuming the user preferred in-person ADHD medication review clinic service, video-link consultations with its past trial-established advantages and this survey of high user satisfaction in its quality, should be retained as an alternative clinic delivery mode.

7.
General Medicine ; 23(6):28-32, 2021.
Article in Bulgarian | Scopus | ID: covidwho-1990085

ABSTRACT

Our aim was to study online self-medication attitudes in Bulgaria towards weight management and stimulation of immune system during COVID-19 pandemic. A short anonymous online survey was published in popular lifestyle and news sites for 1 month. Using HTML5 banner technology, a banner-survey was programmed, collecting the data from user’s behavior and evaluated the number of interactions and answers received. We used marketing tools to receive health related data, trying to combine creative and user-friendly design with serious health topic, in order to receive large scale sincere responses. The survey was shown 4,449,653 times and had 33,544 unique interactions. 57% of people, who answered the first question, refrain from online self-medication. Majority of users, who answered positive, would purchase online a weight control medication or supplement to stay in shape and immunostimulants ‒ to solve health problem. The trends shown in our study indicate the importance of Internet as platform for health education in Bulgaria, where healthcare providers should take a leading role. Bulgarian Regulatory bodies are taking measures to regulate the usage and online purchase of herbal products and medications, but still risks from online self-medications are much greater than potential benefits. The respondents were targeted at the place of their activity – online and therefore the answers were genuine and honest. The high activity proved digital channels’ potential for both receiving and providing health information and education. © 2021, Central Medical Library Medical University – Sofia. All rights reserved.

8.
JMIR Form Res ; 6(5): e30897, 2022 May 31.
Article in English | MEDLINE | ID: covidwho-1951918

ABSTRACT

BACKGROUND: Evidence suggests that economic, social, and psychological circumstances brought about by the COVID-19 pandemic may have a serious impact on behavioral health. Men who have sex with men (MSM) are disproportionally impacted by HIV and stimulant use, the co-occurrence of which heightens HIV transmission risk and undermines nationwide treatment strategies as prevention efforts for ending the HIV epidemic. There is a paucity of information regarding the potential impact of the COVID-19 pandemic on the substance use and HIV medication adherence in this key vulnerable population-MSM who use stimulants and are living with HIV. OBJECTIVE: The aim of this qualitative study was to identify ways in which the COVID-19 pandemic has affected stimulant use and antiretroviral therapy (ART) adherence among a sample of MSM living with HIV. METHODS: Two focus groups were conducted in August 2020 via videoconferencing technology compliant with the Health Insurance Portability and Accountability Act. Potential participants from an established research participant registry at State University of New York Downstate Health Sciences University were invited and screened for study participation on the basis of inclusion criteria. A semistructured interview guide was followed. A general inductive approach was used to analyze the data. Findings in two general areas of interest, the impact of the COVID-19 pandemic on stimulant use and ART adherence, emerged directly from the raw data. RESULTS: A total of 12 ethnically diverse participants over the age of 25 years took part in the study. Results were heterogeneous in terms of the effects of the pandemic on both stimulant use and ART adherence among MSM living with HIV. Some men indicated increased or sustained stimulant use and ART adherence, and others reported decreased stimulant use and ART adherence. Reasons for these behavioral changes ranged from concerns about their own health and that of their loved ones to challenges brought about by the lack of daily structure during the lockdown phase of the pandemic and emotion regulation difficulties. CONCLUSIONS: The COVID-19 pandemic has had a differential impact on stimulant use and ART medication adherence among MSM living with HIV. The reasons for behavioral change identified in this study may be salient intervention targets to support ART medication adherence and lower stimulant use among MSM in the aftermath of the of the COVID-19 pandemic, as well as beyond.

9.
AJPM Focus ; 1(1): 100007, 2022 Sep.
Article in English | MEDLINE | ID: covidwho-1895047

ABSTRACT

Introduction: Stay-at-home orders during the COVID-19 pandemic decreased population mobility to reduce SARS-CoV-2 infection rates. We empirically tested the hypothesis that this public health measure was associated with a higher likelihood of opioid- and stimulant-involved deaths occurring in homes located in Cook County, Illinois. Methods: The stay-at-home period was from March 21, 2020 to May 30, 2020. We analyzed overdose data from the Cook County Medical Examiner's Office using a death location description from case investigations categorized as home, medical, motel, scene, and other. Two groups of decedents were defined as either having an opioid or stimulant listed in the primary cause of death field. We modeled a weekly time series to detect changes in deaths (number) and trends during segmented time periods. Chi-square or Fisher's exact and adjusted logistic regression was used for testing the differences between the stay-at-home and a 13-week preceding period. Results: There were 4,169 and 2,012 opioid- and stimulant-involved deaths, respectively, from 2018 to 2020. Both groups were demographically similar: 75% male, 52% White, and aged 45 years (mean). In the 13 weeks before stay-at-home orders, 51% of opioid-involved deaths occurred in homes, which increased to 59% (p<0.0001) during the 10 weeks of the order and decreased back to 51% in the 18 weeks after the order expired. For stimulant-involved deaths, 51% were residential immediately before the orders, with a nonsignificant increase to 52% during the stay-at-home period. Before the pandemic, there were 20 deaths/week, increasing to 37 deaths/week (p<0.0001) during stay-at-home enactment. Deaths involving fentanyl among the opioid-involved group increased from 76% to 89%, whereas those involving heroin decreased from 55% to 37%. The adjusted OR for opioid-involved fatal overdoses occurring at home during this period compared with that occurring the 13 weeks before was 1.37 (95% CI=1.05, 1.79). Conclusions: The likelihood of a death occurring at home, especially for people using opioids, increased during the stay-at-home order period. Findings have implications for mitigating overdose risks during social isolation.

10.
Child Adolesc Psychiatr Clin N Am ; 31(3): 531-551, 2022 07.
Article in English | MEDLINE | ID: covidwho-1889279

ABSTRACT

The transition from adolescence to adulthood is a complex period in which multiple changes take place (education, work, independent living, and social relations). This stage is especially difficult for adolescents suffering from attention deficit hyperactivity disorder (ADHD), who have to move on from child and adolescent mental health services to adult mental health services. This review analyzes developmental and environmental risk and protective factors as well as critical variables such as executive functioning and self-monitoring that influence the course of ADHD in transitional age youth and guide the priorities for an optimal transition of care. The influence of the COVID-19 pandemic is also discussed. We reflect on the unmet needs for an optimal transition of care and propose practice and policy recommendations to achieve this goal.


Subject(s)
Attention Deficit Disorder with Hyperactivity , COVID-19 , Central Nervous System Stimulants , Mental Health Services , Methylphenidate , Adolescent , Adult , Attention Deficit Disorder with Hyperactivity/drug therapy , Child , Humans , Methylphenidate/therapeutic use , Pandemics , Young Adult
11.
Am J Epidemiol ; 191(7): 1280-1282, 2022 Jun 27.
Article in English | MEDLINE | ID: covidwho-1852932

ABSTRACT

The United States has been in the grip of an epidemic of drug overdose mortality for the past few decades, and deaths from drug overdose increased dramatically during the coronavirus disease 2019 pandemic. Townsend et al. (Am J Epidemiol. 2022;191(4):599-612) add to the growing literature highlighting the steep rise of drug overdose mortality among racial and ethnic minorities in the country. Using data from National Center for Health Statistics death certificates and employing principles of small-area estimation and a Bayesian hierarchical model to stabilize the estimates of smaller racial/ethnic groups and states, the authors found that combinations of opioid/stimulant drug overdose deaths saw a steep increase among racial and ethnic minorities, particularly Black Americans, between 2007 and 2019. The results from their analysis highlight the need to change the narrative around opioid deaths, to invest in targeted policies that address the growing burden of drug overdose faced by racial/ethnic minorities, and the importance of using innovative methods to address limitations to data disaggregation. The paper also demonstrates the importance of a holistic view of the challenges to the health of the American public.


Subject(s)
COVID-19 , Drug Overdose , Black or African American , Analgesics, Opioid , Bayes Theorem , Humans , United States/epidemiology
12.
Int J Drug Policy ; 104: 103679, 2022 06.
Article in English | MEDLINE | ID: covidwho-1773262

ABSTRACT

BACKGROUND AND AIMS: Wastewater-based epidemiology (WBE) is a complementary epidemiological data source to monitor stimulant consumption. The aims were to: (i) study intra- and inter-year temporal changes in stimulant use in Belgium during the first wave of the COVID-19 pandemic; and (ii) evaluate the effect of COVID-19 restrictive measures on stimulant consumption. METHODS: The study population corresponded to the catchments of four wastewater treatment plants corresponding with four Belgian cities (i.e., Antwerp-Zuid, Boom, Brussels, Leuven). Daily 24-h composite influent wastewater samples collected over one week in September 2019 and March through June 2020 during the first wave of the COVID-19 pandemic were analyzed for biomarkers of amphetamine, cocaine, methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA). Measured concentrations were converted to population-normalized mass loads by considering the daily flow rate and the catchment population size. Mobile network data was used to accurately capture population movements in the different catchment areas. Temporal changes were assessed with multiple linear regression models, and the effect of the COVID-19 interventions on stimulant consumption were investigated. RESULTS: An increase in amphetamine use was observed in three cities during governmental restrictions, with highest consumption predominantly during lockdown. Similarly, cocaine consumption was higher after the pandemic started, with highest consumption noted during the lockdown period in Boom and Leuven. Consumption of MDMA was similar in Antwerp-Zuid, Brussels and Leuven throughout the entire sampled period. In Boom, the highest consumption was observed during the full lockdown period. CONCLUSIONS: The present study shows the potential of WBE to assess the impact of stringent lockdown measures on stimulant use in Belgium. This paper shows that strong restrictive measures did not have a profound effect on stimulant consumption.


Subject(s)
COVID-19 , Central Nervous System Stimulants , Cocaine , N-Methyl-3,4-methylenedioxyamphetamine , Amphetamines , Belgium/epidemiology , COVID-19/epidemiology , Communicable Disease Control , Humans , N-Methyl-3,4-methylenedioxyamphetamine/analysis , Pandemics , Substance Abuse Detection , Wastewater/analysis
13.
Drug Alcohol Depend ; 232: 109231, 2022 03 01.
Article in English | MEDLINE | ID: covidwho-1768035

ABSTRACT

BACKGROUND: During the COVID-19 pandemic in 2020, concerns were raised about the potential impact of pandemic-related social distancing measures on existing health disparities among sexual and gender minority (SGM) young adults, including HIV transmission risk and intimate partner violence (IPV). Another concern was the potential for increased methamphetamine use during the pandemic, which is a known risk factor for HIV transmission and IPV. METHODS: The present analysis examines the impact of COVID-19 social distancing (social distancing and quarantining) and methamphetamine use on HIV risk and IPV in a combined dataset from 3 cohort studies of SGM young adults (two in Los Angeles and one in Chicago) from May 2020 to April 2021 (n = 1142). Bivariate analyses and multivariable logistic regressions were estimated. RESULTS: The median age was 26. All participants were assigned male at birth and most participants were men (93.8%). The largest racial groups were Hispanic/Latinx (44.6%) and Black (29.0%). In adjusted models methamphetamine use was consistently associated with having a new sex partner, higher numbers of sex partners, and experience of IPV, during the pandemic. Reporting no social distancing and reporting one social distancing behavior, were associated with experience of IPV relative to reporting 2 social distancing behaviors. Social distancing was not associated with sexual risk behavior or Pre-exposure Prophylaxis use. CONCLUSIONS: SGM young adults live at the intersection of multiple vulnerabilities during the COVID-19 pandemic. Addiction services, HIV prevention services, and violence support services should be prepared to support young adult SGM needs, particularly those who use methamphetamine.


Subject(s)
COVID-19 , Intimate Partner Violence , Methamphetamine , Sexual and Gender Minorities , Adult , COVID-19/epidemiology , COVID-19/prevention & control , Humans , Infant, Newborn , Male , Pandemics , Physical Distancing , SARS-CoV-2 , Young Adult
14.
Polymers (Basel) ; 14(5)2022 Feb 22.
Article in English | MEDLINE | ID: covidwho-1742589

ABSTRACT

The medical term xerostomia refers to the subjective sensation of oral dryness. The etiology seems to be multifactorial with the most frequently reported causes being the use of xerostomic medications, neck and head radiation, and systematic diseases (such as Sjögren's syndrome). Xerostomia is associated with an increased incidence of dental caries, oral fungal infections, and difficulties in speaking and chewing/swallowing, which ultimately affect the oral health-related quality of life. The development of successful management schemes is regarded as a highly challenging project due to the complexity of saliva. This is why, in spite of the fact that there are therapeutic options aiming to improve salivary function, most management approaches are alleviation-oriented. In any case, polymers are an integral part of the various formulations used in every current treatment approach, especially in the saliva substitutes, due to their function as thickening and lubricating agents or, in the case of mucoadhesive polymers, their ability to prolong the treatment effect. In this context, the present review aims to scrutinize the literature and presents an overview of the role of various polymers (or copolymers) on either already commercially available formulations or novel drug delivery systems currently under research and development.

16.
J Med Toxicol ; 17(4): 397-410, 2021 10.
Article in English | MEDLINE | ID: covidwho-1359970

ABSTRACT

During the current global COVID-19 pandemic and opioid epidemic, wastewater-based epidemiology (WBE) has emerged as a powerful tool for monitoring public health trends by analysis of biomarkers including drugs, chemicals, and pathogens. Wastewater surveillance downstream at wastewater treatment plants provides large-scale population and regional-scale aggregation while upstream surveillance monitors locations at the neighborhood level with more precise geographic analysis. WBE can provide insights into dynamic drug consumption trends as well as environmental and toxicological contaminants. Applications of WBE include monitoring policy changes with cannabinoid legalization, tracking emerging illicit drugs, and early warning systems for potent fentanyl analogues along with the resurging wave of stimulants (e.g., methamphetamine, cocaine). Beyond drug consumption, WBE can also be used to monitor pharmaceuticals and their metabolites, including antidepressants and antipsychotics. In this manuscript, we describe the basic tenets and techniques of WBE, review its current application among drugs of abuse, and propose methods to scale and develop both monitoring and early warning systems with respect to measurement of illicit drugs and pharmaceuticals. We propose new frontiers in toxicological research with wastewater surveillance including assessment of medication assisted treatment of opioid use disorder (e.g., buprenorphine, methadone) in the context of other social burdens like COVID-19 disease.


Subject(s)
Biomarkers/analysis , Illicit Drugs/analysis , Pharmaceutical Preparations/analysis , Substance Abuse Detection/methods , Wastewater-Based Epidemiological Monitoring , Wastewater/chemistry , Water Pollutants, Chemical/analysis , COVID-19/epidemiology , Humans , Pandemics , SARS-CoV-2 , Substance-Related Disorders/epidemiology
17.
Int J Drug Policy ; 98: 103392, 2021 12.
Article in English | MEDLINE | ID: covidwho-1330756

ABSTRACT

BACKGROUND: Reports analyzing drug overdose (OD) mortality data during the COVID-19 pandemic are limited. Outcomes across states are heterogenous, necessitating assessments of associations between COVID-19 and OD deaths on a state-by-state level. This report aims to analyze trends in OD deaths in Massachusetts during COVID-19. METHODS: Analyzing 3,924 death records, we characterize opioid-, cocaine-, and amphetamine-involved OD mortality and substance co-presence trends from March 24-November 8 in 2020 as compared to 2018 and 2019. RESULTS: OD deaths involving amphetamines increased by 85% from 2019 to 2020 (61 vs. 113; P<0.001) but were steady from 2018 to 2019. Heroin's presence continued to decrease (341 in 2018, 247 in 2019, 157 in 2020; P<0.001); however, fentanyl was present in more than 85% of all OD deaths across all periods. Among OD deaths, alcohol involvement consistently increased, present in 250 deaths in 2018, 299 in 2019 (P=0.02), and 350 in 2020 (P=0.04). In 2019, 78% of OD decedents were White and 7% were Black, versus 73% and 10% in 2020 (P=0.02). CONCLUSION: Increased deaths involving stimulants, alcohol, and fentanyl reflect concerning trends in the era of COVID-19. Rising OD death rates among Black residents underscore that interventions focused on racial equity are necessary.


Subject(s)
COVID-19 , Drug Overdose , Analgesics, Opioid , Drug Overdose/epidemiology , Fentanyl , Humans , Pandemics , SARS-CoV-2 , United States
18.
Front Pharmacol ; 12: 596855, 2021.
Article in English | MEDLINE | ID: covidwho-1226982

ABSTRACT

The coronavirus disease 2019 (COVID-19) pandemic is caused by an infectious novel strain of coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which was earlier referred to as 2019-nCoV. The respiratory disease is the most consequential global public health crisis of the 21st century whose level of negative impact increasingly experienced globally has not been recorded since World War II. Up till now, there has been no specific globally authorized antiviral drug, vaccines, supplement or herbal remedy available for the treatment of this lethal disease except preventive measures, supportive care and non-specific treatment options adopted in different countries via divergent approaches to halt the pandemic. However, many of these interventions have been documented to show some level of success particularly the Traditional Chinese Medicine while there is paucity of well reported studies on the impact of the widely embraced Traditional African Medicines (TAM) adopted so far for the prevention, management and treatment of COVID-19. We carried out a detailed review of publicly available data, information and claims on the potentials of indigenous plants used in Sub-Saharan Africa as antiviral remedies with potentials for the prevention and management of COVID-19. In this review, we have provided a holistic report on evidence-based antiviral and promising anti-SARS-CoV-2 properties of African medicinal plants based on in silico evidence, in vitro assays and in vivo experiments alongside the available data on their mechanistic pharmacology. In addition, we have unveiled knowledge gaps, provided an update on the effort of African Scientific community toward demystifying the dreadful SARS-CoV-2 micro-enemy of man and have documented popular anti-COVID-19 herbal claims emanating from the continent for the management of COVID-19 while the risk potentials of herb-drug interaction of antiviral phytomedicines when used in combination with orthodox drugs have also been highlighted. This review exercise may lend enough credence to the potential value of African medicinal plants as possible leads in anti-COVID-19 drug discovery through research and development.

19.
Environ Int ; 153: 106540, 2021 08.
Article in English | MEDLINE | ID: covidwho-1157276

ABSTRACT

The COVID-19 outbreak has forced countries to introduce severe restrictive measures to contain its spread. In particular, physical distancing and restriction of movement have had important consequences on human behaviour and potentially also on illicit drug use and supply. These changes can be associated with additional risks for users, in particular due to reduced access to prevention and harm reduction activities. Furthermore, there have been limitations in the amount of data about drug use which can be collected due to restrictions. To goal of this study was to obtain information about potential changes in illicit drug use impacted by COVID-19 restrictions. Wastewater samples were collected in seven cities in the Netherlands, Belgium, Spain and Italy at the beginning of lockdowns (March-May 2020). Using previously established and validated methods, levels of amphetamine (AMP), methamphetamine (METH), MDMA, benzoylecgonine (BE, the main metabolite of cocaine) and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THC-COOH, main metabolite of tetrahydrocannabinol (THC)) were measured and compared with findings from previous years. Important differences in levels of consumed drugs were observed across the considered countries. Whilst for some substances and locations, marked decreases in consumption could be observed (e.g., 50% decrease in MDMA levels compared to previous years). In some cases, similar or even higher levels compared to previous years could be found. Changes in weekly patterns were also observed, however these were not clearly defined for all locations and/or substances. Findings confirm that the current situation is highly heterogeneous and that it remains very difficult to explain and/or predict the effect that the present pandemic has on illicit drug use and availability. However, given the current difficulty in obtaining data due to restrictions, wastewater analysis can provide relevant information about the situation at the local level, which would be hard to obtain otherwise.


Subject(s)
COVID-19 , Illicit Drugs , Substance-Related Disorders , Water Pollutants, Chemical , Belgium , Cities , Communicable Disease Control , Humans , Italy , Netherlands , SARS-CoV-2 , Spain , Substance Abuse Detection , Substance-Related Disorders/epidemiology , Wastewater/analysis , Water Pollutants, Chemical/analysis
20.
J Atten Disord ; 25(13): 1783-1790, 2021 11.
Article in English | MEDLINE | ID: covidwho-664720

ABSTRACT

Background: ADHD limits the ability to comply with Covid-19 prevention recommendations. We hypothesized that ADHD constitutes a risk factor for Covid-19 infection and that pharmacotherapy may lower that risk. Methods: Study population included all subjects (N = 14,022) registered with Leumit Health Services between February 1st and April 30, 2020, who underwent at least one Covid-19 test. Data were collected from the electronic health records. Purchasing consecutively at least three ADHD-medication-prescriptions during past year was considered drug-treatment. Results: A total of 1,416 (10.1%) subjects (aged 2 months-103 years) were Covid-19-positive.They were significantly younger, and had higher rates of ADHD (adjOR 1.58 (95% CI 1.27-1.96, p < .001) than Covid-19-negative subjects. The risk for Covid-19-Positive was higher in untreated-ADHD subjects compared to non-ADHD subjects [crudeOR 1.61 (95% CI 1.36-1.89, p < .001)], while no higher risk was detected in treated ones [crudeOR 1.07 (95% CI 0.78-1.48, p = .65)]. Conclusion: Untreated ADHD seems to constitute a risk factor for Covid-19 infection while drug-treatment ameliorates this effect.


Subject(s)
Attention Deficit Disorder with Hyperactivity , COVID-19 , Central Nervous System Stimulants , Adolescent , Adult , Aged , Aged, 80 and over , Attention Deficit Disorder with Hyperactivity/drug therapy , Attention Deficit Disorder with Hyperactivity/epidemiology , Central Nervous System Stimulants/therapeutic use , Child , Child, Preschool , Drug Prescriptions , Humans , Infant , Middle Aged , Risk Factors , SARS-CoV-2 , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL